GRAIL is trading 5.5% up today at $73.99, attempting to recover from steep losses tied to a failed NHS-Galleri cancer trial and subsequent allegations of securities fraud.
- Recent coverage highlights upcoming class-action deadlines following February’s surprise trial miss, which erased more than $2.2 billion in market value.
- Despite the current price rebound, the company faces persistent legal and reputational risks as investors weigh the impact of the clinical failure.